Business · 13/07/2001Updated: 10/17/2026 · 1 min read
FDA Issues Guidance on Levothyroxine Sodium Products Post-Compliance Date
Summary
The Food and Drug Administration (FDA) has released a new guidance document outlining its approach to enforcing compliance with levothyroxine sodium product regulations, effective August 14, 2001, and providing answers to frequently asked questions regarding new applications for these products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →